Skip to content

Calcitonin in shoulder adhesive capsulitis

Evaluation of Calcitonin effects on shoulder adhesive capsulitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210223050470N1
Enrollment
100
Registered
2021-05-22
Start date
2021-06-22
Completion date
Unknown
Last updated
2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adhesive capsulitis of shoulder. Adhesive capsulitis of shoulder

Interventions

Intervention 1: Intervention group: this group receives nasal calcitonin spray. It should be used with dosage of one puff daily for 8 weeks. Intervention 2: Control group: this group does not receive

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with adhesive capsulitis (Diagnostic criterion: 1. Shoulder pain and stiffness for at least 4 weeks 2. Severe shoulder pain that restricts daily activities 3. Nocturnal pain 4. Limitation in active and passive range of motion Patients in first stage of disease( Progressive pain and limitation in range of motion from past 3 months.) Patient agreement to enter the trial 30 to 60 years old patients

Exclusion criteria

Exclusion criteria: Patients with history of trauma, surgery, corticosteroid injection or any previous injury to the shoulder Patients who had received other treatments including surgical or nonsurgical treatments prior to entering the trial

Design outcomes

Primary

MeasureTime frame
Pain severity. Timepoint: Before starting the intervention, 2 months and 6 months after starting the intervention. Method of measurement: By Visual Analogue Scale( VAS ).;Shoulder range of motion. Timepoint: Before starting the intervention, 2 months and 6 months after starting the intervention. Method of measurement: By physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Dehghani

Esfahan University of Medical Sciences

shakibadehghanii@gmail.com0098316688644

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026